Neuroendocrine Differentiation in Renal Cell Carcinoma: Evaluation of Chromogranin A and Neuron-Specific Enolase

REFERENCES

• Smith AD, Winkler H. Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla. Biochem J 1967; 103: 483–92.
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Frigon RP. Chromogranin A, the major cate-cholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984; 259: 3237–47.
   Google Scholar
• Deftos U. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. En-docr Rev 1991; 12: 181–7.
   PubMed Web of Science ®Google Scholar
• Wilson BS, Lloyd RV. Detection of chromogranin in neu-roendocrine cells with a monoclonal antibody. Am J Pathol 1984; 115: 458–68.
   PubMed Web of Science ®Google Scholar
• Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HPH, O'Connor DT. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimula-tion of endocrine glands. J Clin Endocrinol Metab 1990; 71: 360–9.
   Google Scholar
• Said JW, Vimadalal S, Nash G, et al. Immunoreactive neu-ron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 1985; 16: 236–40.
   PubMed Web of Science ®Google Scholar
• Heiman LJ, Gazdar AF, Park J-G, Cohen PS, Cotelingam JD, Israel MA. Chromogranin A expression in normal and malignant human tissues. J Clin Invest 1988; 82: 686–90.
   PubMedGoogle Scholar
• Abrahamsson PA, Falkmer S, Fah K, Grimelius L. The course of neuroendocrine differentiation in prostatic car-cinomas. An immunohistochemical study testing chro-mogranin A as an 'endocrine marker'. Path Res Pract 1989; 185: 373–80.
   Google Scholar
• Pagani A, Papotti M, Haler H, Weiler R, Winkler H, Busso-lati G. Chromogranin A and B gene expression in carcinomas of the breast. Correlation of immunocytochemical, im-munoblot, and hybridization analyses. Am J Pathol 1990; 136: 319–27.
   Google Scholar
• Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of chro-mogranin A and neuron specific enolase in pulmonary adeno-carcinoma. Ann Oncol 1991; 2: 355–60.
   Google Scholar
• Park J-G, Choe GY, Heiman LJ, et al. Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer 1992; 51: 189–94.
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Deftos U. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145–51.
   PubMed Web of Science ®Google Scholar
• O'Connor DT, Pandian MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989; 35: 1631–7.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Arnberg H, Oberg K, et al. A polyclonal anti-serum against chromogranin A and B-a new sensitive marker for neuroendocrine tumours. Acta Endocrinol (Copenh) 1990; 122: 145–55.
   PubMedGoogle Scholar
• Kadmon D, Thompson TC, Lynch GR, Scardino PT. Ele-vated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146: 358–61.
   PubMed Web of Science ®Google Scholar
• Syversen U, Halvorsen T, Marvik R, Waldum HL. Neuroen-docrine differentiation in colorectal carcinomas. Eur J Gas-troenterol Hepatol 1995; 7: 667–74.
   PubMed Web of Science ®Google Scholar
• Haimoto H, Takashi M, Koshikawa T, Asai J, Kato K. Enolase isozymes in renal tubules and renal cell carcinoma. Am J Pathol 1986; 124: 488–95.
   Google Scholar
• Takashi M, Haimoto H, Tanaka J, Murase T, Kato K. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. J Urol 1989; 141: 830–4.
   Google Scholar
• Rasmuson T, Grankvist K, Ljungberg B. Serum 7-enolase and prognosis of patients with renal cell carcinoma. Cancer 1993; 72: 1324–8.
   Google Scholar
• Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297–301.
   Google Scholar
• Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbet-ter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28: 1165–77.
   Google Scholar
• Gazdar AF, Heiman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-Dopa decarboxylase, chro-mogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988; 48: 4078–82.
   PubMed Web of Science ®Google Scholar
• Edgren M, Stridsberg M, Kälknar K-M, Nilsson S. Neuroen-docrine markers; chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell car-cinoma. Anticancer Res 1996; 16: 3871–4.
   Google Scholar
• Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955–64.
   Google Scholar
• Cubeddu LX, O'Connor DT, Hoffmann I, Parmer RJ. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophos-phamide-based chemotherapies. Br J Cancer 1995; 72: 1033–8.
   PubMed Web of Science ®Google Scholar
• Nobels FRE, Kwekkeboom DJ, Coopmans W, et al. Chro-mogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622–8.
   PubMed Web of Science ®Google Scholar